The Trump executive order aimed at lowering prescription drug prices focuses on several strategies, including allowing for the importation of cheaper drugs from other countries, improving price transparency, and giving states more authority to negotiate drug prices. It's meant to take effect within 30 days, although specific timelines depend on regulatory approval. A Presidential executive order can't directly dictate price points for private industries, but it can create new regulations that influence pricing strategies. The impact is more indirect, driving pressure on pharmaceutical companies to lower prices due to market shifts and public policy changes. While Congress and the courts could theoretically intervene and challenge the order, the likelihood of successful challenges is low unless there's a constitutional issue at stake, given the executive branch's authority in regulating certain industries. Companies like Pfizer and Merck could face more pressure due to their broad market influence and pricing strategies. Biotech investors should keep an eye on stocks with heavy exposure to U.S. drug prices—adjusting strategies to hedge against regulatory impacts may be wise.